very interesting- the primary endpt is pain at the injection site reported by the patient. so this new formulation would be the basis of an ANDA because of the differences between it and the original copaxone?
obviously, if one of the undisclosed teva-antares programs is for either lovenox or copaxone, that would be hugely consequential for a tiny company like AIS
Market Data 
Markets 
AI
